TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06763848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protein A immunoadsorption
Description: The experimental group was treated with a combination of protein A immunoadsorption and intravenous methylprednisolone. The methylprednisolone was administered following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day. Protein A immunoadsorption was conducted every other day, unless a physician determined that the patient's condition was unsuitable for treatment, in which case treatment was administered according to medical advice. A total of 5 treatments were given, with each session involving the regeneration of plasma at 1 to 3 times the plasma volume.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous methylprednisolone
Description: The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.
Study: NCT04041232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA
Description: Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
Study: NCT05214989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
Study: NCT06325280

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI Assessment
Description: Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI Assessment
Description: Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
Study: NCT05542810

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Use sports drinks as polyethylene glycol solvents
Description: Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
Study: NCT05217095

Intervention type: DEVICE
Group type: OTHER
Intervention: Convergence Dialyzer
Description: The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
Study: NCT05994209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quitSTART Mobile Application
Description: Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quitSTART Mobile Application
Description: Mobile application with educational content, motivational messages, self-monitoring, and tips for managing cravings to support vaping cessation among young adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot Feature in quitSTART Mobile Application
Description: In-App chatbot feature emedded into quitSTART mobile application to motivate vaping cessation and support app navigation.
Study: NCT06184711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme
Description: The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme
Description: The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
Study: NCT06390085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue manipulation
Description: The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue manipulation
Description: The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue manipulation
Description: The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
Study: NCT05545319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
Study: NCT06384521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle MIND
Description: Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle MIND
Description: Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
Study: NCT04879121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO
Study: NCT05545319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours
Study: NCT06184711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
Study: NCT05545319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study: NCT05918289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended& integrated happy aging active aging program(BIHAAAP)
Description: 12 Weeks intervention devided in to two phases( face to face and home based)
Study: NCT05235997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolized Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo look alike the experimental product
Study: NCT06489535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAIN
Description: There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unrelated videos
Description: These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
Study: NCT06363513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aescin in Horse Chestnut
Description: Can aescin reduce bleeding in early hemorrhoid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid
Description: Can combine aescin and MPFF reduce bleeding in early hemorrhoid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonoid
Description: Can combine aescin and MPFF reduce bleeding in early hemorrhoid
Study: NCT05954156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: injectable composite
Description: The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable composite
Description: The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
Study: NCT04896346

Intervention type: OTHER
Intervention: Punch biopsy
Description: punch biopsies will be used for histologic analysis and biochemical assays

Intervention type: OTHER
Intervention: Punch biopsy
Description: punch biopsies will be used for histologic analysis and biochemical assays

Intervention type: OTHER
Intervention: non-invasive photography, assessments, and measurements
Description: photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity

Intervention type: OTHER
Intervention: non-invasive photography, assessments, and measurements
Description: photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
Study: NCT06140758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Toms of Maine 0 ppm Fluoride Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1100 ppm (0.454% Stannous fluoride) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study: NCT05534919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon
Description: Nefecon is taken orally as capsules once daily for 9 months.
Study: NCT06320717

Intervention type: OTHER
Intervention: Blood sample
Description: To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients

Intervention type: OTHER
Intervention: Blood sample
Description: To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
Study: NCT04719052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and behavioural intervention
Description: Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
Study: NCT05626114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpRegen
Description: OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
Study: NCT05729282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide oral suspension, 1 mg per kg per dose
Description: Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide oral suspension, 2 mg per kg per dose
Description: Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
Study: NCT04719052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and behavioural intervention
Description: Control group will receive a specific diet designed following the characteristics of Low fat Diet.
Study: NCT05729282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FreeStyle Libre Pro
Description: All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated water (2H2O/D2O)
Description: All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated water (2H2O/D2O)
Description: All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deuterated water (2H2O/D2O)
Description: All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
Study: NCT06332547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion Strategy
Description: Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
Study: NCT04930692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT lymphography with the periareolar injection of iopamidol
Description: Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator.
Study: NCT06332547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Transfusion Strategy
Description: Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
Study: NCT06411730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days
Study: NCT04894526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating Energy Intake
Description: To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Energy Intake
Description: To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
Study: NCT06364358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized CKD Education
Description: The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Hospital Care
Description: Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
Study: NCT06194799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-204
Description: ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule